Evidence map›Paper›PMID 33659947›Full record

ReviewFaculty reviews2020

Recent advances in understanding cholangiocarcinoma.

Pedro Luiz Serrano Uson Junior, Mansi Arora, James M Bogenberger, Mitesh J Borad

Abstract readReview
In one paragraph

Review in Faculty reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pedro Luiz Serrano Uson JuniorDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
Mansi AroraDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
James M BogenbergerDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
Mitesh J BoradDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The definition of cholangiocarcinoma (CCA) encompasses all tumors originating in the epithelium of the bile ducts, including the intrahepatic bile ducts (ICCA) and extrahepatic bile ducts (ECCA). The incidence of ICCA and ECCA has increased in the last few decades, and molecular advances in both entities have brought understanding of their differences and allowed treatment advances aimed at personalized therapy. In this review, we discuss recent progress in the molecular landscape of CCAs, emerging treatment biomarker-guided strategies, and future insights into the management of advanced disease.

Indexed as

biliary tract cancerCholangiocarcinomaFGFR2IDH1PD-1

Identifiers

PMID33659947
PMCPMC7886064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.